KY1005の中等度から重度のアトピー性皮膚炎に対する反応効果を検証する研究、STREAM-AD試験

基本情報

NCT ID

NCT05131477

ステータス

完了

試験のフェーズ

第2相

試験タイプ

介入

目標被験者数

390

治験依頼者名

Kymab Limited

概要

This is an interventional, randomized, parallel group, treatment, Phase IIb, double blind, 5-arm study to assess the effect of Anti-OX40L Monoclonal Antibody (KY1005) in adult participants with moderate to severe atopic dermatitis. The estimated duration is 28 days for screening and then up to approximately day 477 (last dose no later than day 337+140 days safety follow-up) for all patients unless enrolled into the Long-Term Extension (LTE) protocol (NCT05492578) at either Day 169 depending on responder status or no later than Day 365 due to loss of clinical response.

対象疾患

介入

依頼者（Sponsor）